Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA
neovascular age-related macular degeneration (nAMD)
Resolved
67days ago
FDA decision · ~ May 1, 2026 estimated
What's at stake
The FDA's approval decision on ONS-5010/LYTENAVA for neovascular age-related macular degeneration (nAMD) is due ~ May 1, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“the FDA has granted a meeting with the deciding official to be conducted in April 2026”